Table 3 Result of post-transplant kidney allograft biopsy.
Variables | Including protocol biopsies | Only for-cause biopsies | ||||
|---|---|---|---|---|---|---|
Total (n = 3712) | Living (n = 2267) | Deceased (n = 1445) | Total (n = 1538) | Living (n = 869) | Deceased (n = 669) | |
Borderline change | 723 (19.5%) | 444 (19.6%) | 279 (19.3%) | 325 (21.1%) | 182 (20.9%) | 143 (21.4%) |
Acute T-cell mediated rejection | 549 (14.8%) | 341 (15.0%) | 208 (14.4%) | 394 (25.6%) | 247 (28.4%) | 147 (22.0%) |
Acute antibody mediated rejection | 263 (7.1%) | 163 (7.2%) | 100 (6.9%) | 214 (13.9%) | 126 (14.5%) | 88 (13.2%) |
Chronic active T cell mediated rejection | 48 (1.3%) | 26 (1.2%) | 22 (1.5%) | 45 (2.9%) | 24 (2.8%) | 21 (3.1%) |
Chronic active antibody mediated rejection | 46 (1.2%) | 27 (1.2%) | 19 (1.3%) | 40 (2.6%) | 22 (2.5%) | 18 (2.7%) |
Interstitial fibrosis and tubular atrophy | 526 (14.2%) | 277 (12.2%) | 249 (17.2%) | 268 (17.4%) | 140 (16.1%) | 128 (19.1%) |
BK nephropathy | 134 (3.6%) | 70 (3.1%) | 64 (4.4%) | 121 (7.9%) | 62 (7.1%) | 59 (8.8%) |
Glomerulonephritis | 206 (5.6%) | 110 (4.9%) | 96 (6.6%) | 149 (9.7%) | 82 (9.4%) | 67 (10.1%) |
Calcineurin inhibitor toxicity | 192 (5.2%) | 95 (4.2%) | 97 (6.7%) | 108 (7.0%) | 58 (6.7%) | 50 (7.5%) |
Others | 765 (20.6%) | 423 (18.7%) | 342 (23.7%) | 410 (26.7%) | 246 (28.3%) | 164 (24.5%) |
